Interested in Connecting? Please contact:
Mr. Stephane Gagne
President & CEO
sgagne@ovensa.com

Message the company or request a 1:1 meeting here

Ovensa is a preclinical stage company developing the only siRNA drug candidate silencing the overexpression of galectin-1 in cancer. It has shown improving therapeutic outcomes of checkpoint inhibitors and chemotherapy in recurrent glioblastoma.

Ovensa has entered into R&D collaborations with large and medium size pharmaceutical companies for using its non-viral and non-lipid TRIOZANTM Nanomedicine Platform for targeted and BBB-crossing drug delivery.

Pitch Video